Halozyme Therapeutics (HALO)

Generated: October 3, 2026

Green Dot

Statistics

Metric	Value
Last Close	$109.85
Blended Price Target	122.63
Blended Margin of Safety	11.6% Undervalued
Rule of 40 (Next)	45.8%
Rule of 40 (Current)	68.2%
FCF-ROIC	35.2%
Sales Growth Next Year	10.6%
Sales Growth Current Year	33.0%
Sales 3-Year Avg	28.7%
Industry	Biotechnology

Analysis

Halozyme is a high-quality biotechnology platform business with an unusually attractive combination of royalty growth, operating leverage, and contractual visibility. Its ENHANZE technology is embedded in commercially successful injectable medicines, allowing Halozyme to participate in partners’ product expansion without bearing the full cost and risk of discovering and commercializing those drugs itself. The second-quarter 2026 results reinforce that model: revenue increased 48% year over year to $481 million, while royalty revenue rose 50% to $308 million.^[6]

The outlook is durable but not automatic. Growth depends on partner execution, continued adoption of subcutaneous formulations, new product launches, and expansion into additional indications and geographies. Halozyme’s moat is strongest where its technology is already integrated into approved products, because regulatory validation and manufacturing know-how make replacement difficult. Leadership under CEO Helen Torley has consistently emphasized disciplined partnering and royalty economics, although the business remains exposed to concentration among a limited number of major pharmaceutical products.

What the Company Does

Halozyme develops drug-delivery technologies that help pharmaceutical companies administer biologic medicines more quickly and conveniently, often by converting intravenous infusions into subcutaneous injections. Its main platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue permeability, enabling larger volumes of medicine to be delivered under the skin. Partners pay licensing fees, milestones, royalties, and, in some cases, product-related payments.

The economic model is increasingly royalty-oriented. Current growth is being driven by partner products such as DARZALEX SC from Janssen, VYVGART Hytrulo from argenx, and Phesgo from Roche, alongside product sales and active pharmaceutical ingredient revenue.^[10] The latest disclosure does not provide a sufficiently clear current percentage breakdown for each revenue category, so the mix is best described qualitatively: royalties are the strategic core, with product sales and other contractual revenue supplementing them.

Revenue Recurrence & Predictability

Halozyme’s revenue is primarily contractual and royalty-based rather than subscription-based. Once a partner product using ENHANZE is approved and commercialized, royalties can continue for as long as the product generates sales under the relevant agreement. This gives the company greater visibility than a project-based biotechnology business, although revenue still depends on prescription demand, product launches, label expansions, and partner execution.

The company does not provide a single current percentage identifying how much revenue is recurring or highly predictable. Qualitatively, the royalty stream is relatively predictable compared with milestone revenue, which can be lumpy and event-driven. Product sales and API revenue are also more transactional, while the growing base of marketed partner products provides diversification across multiple programs and pharmaceutical companies.

Revenue Growth Durability

Halozyme can plausibly sustain above-market growth for several years if the current portfolio continues expanding and new ENHANZE products reach the market. The first-quarter 2026 release cited continued uptake of products launched since 2020 and guided to 2026 revenue growth of 22% to 30%, primarily from royalty revenue and API product sales.^[10] The second-quarter result showed that momentum continued through June.^[6]

The main growth levers are additional approvals, conversion of intravenous therapies to subcutaneous delivery, geographic expansion, indication growth, and new licensing agreements. The addressable opportunity is supported by pharmaceutical companies’ interest in improving patient convenience, reducing infusion-center burden, and extending the commercial life of established biologic products. Headwinds include slower-than-expected adoption, partner delays, competing delivery technologies, and eventual patent or exclusivity expiry.

Economic Moat

Halozyme’s moat rests on regulatory experience, accumulated formulation and manufacturing expertise, partner relationships, and the difficulty of replacing an approved delivery system inside an established drug product. Once ENHANZE is incorporated into a commercial formulation, a competing technology would generally need to demonstrate comparable performance, complete development work, and obtain regulatory approval. That creates meaningful switching costs for partners.

The moat is not a network effect in the conventional technology-company sense, and Halozyme does not possess a permanent monopoly over subcutaneous delivery. Its advantage is strongest in programs already validated commercially and in the know-how accumulated across multiple collaborations. The moat appears to be widening as more partner products generate real-world evidence, royalties, and manufacturing scale, but it could narrow if alternative delivery platforms become easier to use or if partners develop proprietary substitutes.

Management & Leadership

Halozyme is not founder-led. Helen Torley has served as chief executive since 2019 and has overseen the company’s shift toward a royalty-focused platform model, including greater emphasis on commercial partnerships and recurring economics. Recent disclosures identify Torley as CEO and show the company maintaining strong operating momentum under that strategy.^[1]^[10]

Insider ownership is not a central part of the investment case, and the latest materials reviewed do not provide a current figure that should be emphasized here. Capital allocation has focused on business development, platform investment, debt and liquidity management, and returning capital through share repurchases when authorized. The notable leadership strength is strategic discipline: Halozyme generally seeks to monetize technology through partners rather than fund full-scale drug commercialization itself.

Key Risks

Customer and product concentration remain important risks. A relatively small number of major pharmaceutical products drive a substantial portion of royalty growth, so a clinical setback, manufacturing problem, reimbursement issue, competitive threat, or weaker-than-expected launch at a partner could materially affect results. Royalty revenue can also become less diversified than the number of agreements suggests if a few blockbusters dominate sales.

Regulatory and technological risks are also significant. Subcutaneous reformulations must satisfy regulators, and partners may delay or abandon programs before commercialization. Competing delivery technologies could reduce the attractiveness of ENHANZE, while manufacturing or supply-chain problems could disrupt API sales or partner launches.

Finally, Halozyme depends on execution across a complex network of licensees. Contract milestones are uneven, product uptake can vary by geography and indication, and intellectual-property protection will eventually weaken for some programs. The company’s model reduces direct clinical-development risk but does not eliminate exposure to pharmaceutical-market cycles, partner priorities, or changes in healthcare reimbursement.

Sources

Featured in GreenDot Stocks Analysis

GreenDot Stocks Screen Update — Week of October 3, 2026 October 3, 2026